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Heart  failure  (HF)  was  identified  as  an  emerging  epidemic
more  than  two  decades  ago,1 and  is  currently  estimated  to
affect  at  least  26  million  people  worldwide.2 HF  is  a  com-
plex  syndrome  that  is  difficult  to  define,  characterized  by
the  heart’s  inability  to  meet  the  body’s  metabolic  demands
resulting  from  structural  and/or  functional  impairment  of
ventricular  filling  or  ejection.3,4 Diagnosis  is  largely  clinical,
based  on  symptoms  and  signs,  for  which  imaging  techniques
(particularly  echocardiography)  and  measurement  of  neu-
rohormonal  peptides  are  crucial.  Although  in  most  cases
the  focus  is  on  symptomatic  HF,  a  proportion  of  high-risk
patients  may  have  no  symptoms  despite  reduced  left  ven-
tricular  ejection  fraction,  and  they  may  also  benefit  from
medical  therapies  that  favorably  impact  prognosis.
Worldwide,  the  overall  prevalence  of  HF  is  about  1-2%,
but  this  figure  increases  considerably  with  advancing  age.
Progress  in  primary  prevention  and  improvements  in  medi-
cal  care  have  resulted  in  improved  survival,  which  in  turn
is  expected  to  lead  to  a  steady  rise  in  the  prevalence  of
HF.  In  the  US,  an  estimated  6.2  million  individuals  aged  ≥20
years  have  HF  (data  from  the  US  National  Health  and  Nutri-
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nd  projections  show  that  the  prevalence  of  HF  will  increase
y  46%  from  2012  to  2030,  resulting  in  >8  million  people  aged
18  years  with  the  condition.5
In  a  recent  paper,  Conrad  et  al.  provided  contemporary
nsight  into  the  magnitude  of  the  HF  burden  in  a  repre-
entative  sample  (four  million  individuals)  of  the  general
opulation  of  the  UK,  between  2002  and  2014.6 They  showed
hat  incidence  (standardized  by  age  and  gender)  decreased
y  7%  over  this  period,  which  appeared  to  be  mainly  driven
y  a  lower  incidence  of  HF  in  people  between  60  and
4  years  of  age.  However,  the  incidence  in  people  aged
5  and  older  increased  substantially  over  the  observation
eriod.  Moreover,  the  authors  found  that  the  absolute  preva-
ence  had  increased  by  23%,  and  attributed  this  increase  to
opulation  growth  and  aging,  in  addition  to  more  people
urviving  a  myocardial  infarction.6
Temporal  trends  in  incidence  are  variable  across  studies
nd  difficult  to  rely  on  due  to  methodological  differ-
nces  regarding  populations,  settings,  and  ascertainment
nd  adjustment  approaches,  but  overall  indicate  that  the
7ncidence  of  HF  is  stable  or  even  decreasing  over  time.
owever,  the  lifetime  risk  for  HF  in  the  community  is  very
igh  (ranging  from  30%  to  40%),8--10 with  traditional  factors
ccounting  for  a  considerable  proportion  of  HF  risk  and  con-


















































































































ributing  to  the  rise  in  HF  prevalence.5 Despite  the  progress
n  therapies  (drugs  and  devices)  observed  during  recent
ecades,  HF  remains  a  morbid,  fatal  and  costly  condition,
ith  a  global  burden  that  will  increase  dramatically  with  an
ging  population.  In  fact  HF  is  the  single  leading  cause  of
ospitalization  in  persons  aged  65  years  and  above.6 Rates
f  hospitalizations  for  HF  are  increasing  over  time,  appar-
ntly  driven  by  rises  in  HF  with  preserved  ejection  fraction
HFpEF).5 Diastolic  dysfunction  is  a  common  condition,  espe-
ially  in  the  elderly,5,11 and  HFpEF  may  soon  be  dominant,  if
t  is  not  already,  in  driving  overall  HF  prevalence.10
HF  constitutes  an  enormous  economic  burden  for  health
are  systems  in  industrialized  countries.  Europe  and  the  US
pend  1-2%  of  their  annual  health  care  budget  on  HF.  Cook
t  al.12 estimated  the  overall  cost  of  heart  failure  in  2012,
n  both  direct  and  indirect  terms,  across  the  globe.  They
ncluded  197  countries  in  the  analysis,  covering  98.7%  of
he  world’s  population.  The  overall  economic  cost  of  HF
n  2012  was  estimated  at  $108  billion  per  annum.  Direct
osts  accounted  for  ∼60%  ($65  billion)  and  indirect  costs
ccounted  for  ∼40%  ($43  billion)  of  the  overall  spend.  The
S  is  the  biggest  contributor  to  global  HF  costs,  accounting
or  28.4%  of  the  total  ($30.7  billion).5,12 Europe  accounts
or  6.83%  of  total  global  HF  costs.12 High-income  countries
pend  a  greater  proportion  on  direct  costs,  while  in  middle-
nd  low-income  countries  a  higher  proportion  is  spent  on
ndirect  costs.12 US  projections  suggest  that  by  2030,  the
otal  cost  of  HF  will  increase  by  127%,  to  $69.8  billion,
mounting  to  ≈$244  for  every  American  adult.5
In  this  issue  of  the  Journal,  Gouveia  et  al.13 present
 cost-of-illness  (COI)  study  on  HF  in  mainland  Portugal,
ollowing  a  prevalence-based  approach  and  the  societal  per-
pective  to  estimate  direct  and  indirect  costs  related  to
F.
On  the  basis  of  the  estimated  prevalence  and  costs  for
014  (the  index  year),  the  authors  estimated  changes  for
he  following  two  decades  (up  to  2036),  considering  only  the
redicted  aging  of  the  population.  Only  the  resident  popula-
ion  ≥25  years  of  age  with  symptomatic  HF  (New  York  Heart
ssociation  [NYHA]  functional  class  II-IV)  was  included.  The
revalence  of  HF  in  2014  was  estimated  on  the  basis  of
he  EPICA  study  (1998-2000),14 adjusted  for  the  expected
hanges  in  demographics  since  that  study.
The  different  settings  experienced  by  HF  patients  were
nalyzed.  Direct  costs  included  hospitalizations,  hospital
utpatient  services,  emergency  department  (ED)  visits  (with
nd  without  hospitalization),  day  hospital  care,  medica-
ions,  transportation,  and  use  of  the  national  network  of
ong-term  care  (nursing  home  hospitalization  or  equivalent).
ata  from  2014  on  hospitalizations  and  hospital  outpatient
ervices  were  estimated  based  mostly  on  data  from  the
ational  Diagnostic-Related  Group  database  and  identified
ccording  to  the  International  Classification  of  Diseases,
inth  Revision,  Clinical  Modification  (ICD-9).  For  the  pur-
oses  of  the  study,  hospitalization  was  attributed  to  HF  when
his  was  listed  as  a  primary  diagnosis,  when  it  was  coded
s  secondary  to  a  primary  diagnosis  of  circulatory  system
isease,  or  when  there  were  invasive  cardiac  procedures
surgery  or  device  implantation)  irrespective  of  other  asso-
iated  diagnoses.  All  procedures  and  interventions  related






zation  episode.  Estimates  of  other  relevant  costs  regarding
ospital  outpatient  services  were  also  derived  from  diverse
ources  of  information,  including  the  opinion  of  a  panel  of  HF
xperts  representing  various  different  geographical  areas.
stimation  of  costs  related  to  primary  care  use  was  preceded
y  a  cross-sectional  study  analyzing  data  from  the  informa-
ion  system  of  the  Lisbon  and  Tagus  Valley  Regional  Health
dministration.  From  a  population  of  1.8  million,  25  316
ndividuals  were  identified  aged  ≥25  years,  with  at  least
ne  medical  visit  during  the  index  year  (2014),  and  a  code
f  HF  (K7  in  the  International  Classification  of  Primary  Care,
econd  edition).  Costs  (including  those  related  to  medical
herapy)  were  obtained  from  the  Lisbon  and  Tagus  Valley
egional  Health  Administration  database.
The  indirect  costs  that  were  considered  corresponded
o  lost  productivity  due  to  lower  employment  rates  or
bsenteeism.13 The  authors  assumed  that  only  patients
nder  65  years  generate  indirect  costs,  and  that  patients
n  NYHA  functional  class  II  generate  only  indirect  costs  for
bsenteeism.
For  the  estimation  of  future  costs,  the  authors  considered
hat  all  variables  and  parameters  that  generate  costs  would
emain  constant,  except  for  the  demographic  composition
f  the  population,  i.e.  they  considered  that  the  mean  cost
er  patient  and  the  prevalence  rates  of  HF  by  gender  and
ge  would  not  vary  over  the  period  considered.
The  estimated  overall  prevalence  of  HF  for  2014  was
.2%  (mainland  Portugal,  population  aged  25  years  of  age  or
ver).  The  prevalence  of  HF  generating  costs  (NYHA  func-
ional  classes  II-IV)  was  3.4%.  The  overall  economic  cost
f  HF  in  2014  was  estimated  at  D  405  million,  represent-
ng  around  0.2%  of  gross  domestic  product  and  2.6%  of  total
ublic  health  expenditure.  Direct  costs  accounted  for  74%
D  299  million),  of  which  39%  was  attributed  to  hospitaliza-
ions,  24%  to  medications,  17%  to  exams  and  tests  and  16%  to
onsultations.  Indirect  costs  accounted  for  26%  (D  106  mil-
ion)  of  the  overall  spend,  84%  of  which  was  for  reduced
mployment  and  16%  for  absenteeism.
According  to  the  authors’  estimated  projections  for  2036
n  mainland  Portugal,  the  number  of  patients  with  HF  (NYHA
unctional  class  II-IV)  will  increase  by  27%  relative  to  2014,
orresponding  to  an  overall  cost  of  D  503  million  in  2036
an  increase  of  24%).  The  increase  in  the  number  of  older
eople  with  HF,  along  with  a  constant  rise  in  direct  costs,
xplains  the  increase  in  total  cost;  a  decrease  in  indirect
osts  is  expected  and  attributed  to  demographic  changes,
s  there  will  be  fewer  people  younger  than  65  years  of
ge  (lower  prevalence  of  HF  and  decreased  indirect  costs).
he  decrease  in  indirect  costs  also  explains  the  discrepancy
etween  the  rate  of  increase  in  total  costs  (27%)  and  the
ate  of  increase  in  the  number  of  patients  with  HF  (24%).
he  annual  cost  per  patient  with  HF  (NYHA  class  II-IV)  is  pre-
icted  decrease  from  ∼D  1623  in  2014  to  ∼D  1582  in  2036,
ut  the  cost  per  head  of  population  will  increase  by  ∼34%
etween  2014  and  2036,  amounting  to  ≈D  55  for  every  adult.
The  overall  picture  in  mainland  Portugal  is  in  line  with
he  international  literature  on  this  subject.  In  a  recent  sys-
ematic  review  (2004-2016)15 of  16  published  COI  studies
ealing  with  the  cost  impact  of  HF,  considerable  variation
as  observed  in  cost  components  and  estimates,  as  the
ethodologies  used  varied  widely  and  health  care  systems




















Heart  failure:  The  value  of  evidence-supported  decision-ma
mated  indirect  costs,  and  four  European  studies  published
between  2013  and  201716--19 focused  mainly  on  costs  related
to  HF  hospitalizations,  while  none  estimated  costs  for  lost
productivity.  However,  most  of  the  16  included  studies15
showed  that  hospitalizations  are  the  most  expensive  ele-
ment.
Also,  according  to  Gouveia  et  al.’s  estimates,13 hospital-
izations  accounted  for  39%  of  direct  costs  while  only  16%
were  attributed  to  consultations,  a  situation  that  urgently
needs  to  be  changed.  Medications  accounted  for  24%  of
direct  costs,  which  is  to  be  expected  considering  the  heavy
pharmacological  burden  of  HF  patients.  The  benefit  pro-
vided  by  prognosis-modifying  therapies  may  outweigh  the
economic  burden  of  hospitalizations,  although  given  the
greater  longevity  achieved  along  with  the  corresponding
increase  in  HF  prevalence,  it  is  difficult  to  expect  a  reduction
in  the  total  cost  of  the  illness.
The  work  by  Gouveia  et  al.13 has  several  merits  besides
being  the  first  study  to  shed  light  on  the  costs  of  HF  in  Portu-
gal  and  the  corresponding  estimated  projection  for  the  next
two  decades.  First,  the  study  covers  the  population  with
HF  in  the  different  possible  contexts  of  management:  the
hospital  setting  (hospitalization,  consultations,  day  hospital
care,  emergency  department  visits  without  hospitalization);
the  community  (outpatient  setting),  i.e.  management  in
primary  health  care;  and  care  at  home  (or  in  an  institu-
tion)  integrated  in  the  National  Network  of  Long-Term  Care.
Second,  the  work  reflects  the  situation  in  Portugal  using  a
methodology  that  appears  flawless,  erring  only  on  the  side  of
underestimation.  In  other  words,  the  cost  estimates  are  con-
servative,  as  stated  by  the  authors,  not  including  variables
for  which  information  is  scarce  or  nonexistent.  These  include
the  following  additional  costs:  those  arising  from  the  large
number  of  patients  who  are  likely  to  be  followed  simultane-
ously  in  two  places  (e.g.  hospital  consultations  and  primary
care);  the  proportion  of  patients  with  reduced  ejection  frac-
tion  but  without  symptoms  (NYHA  functional  class  I)  who
may  be  under  pharmacological  therapy  and  hence  generate
costs;  cardiac  rehabilitation  programs  (for  which  there  are
no  published  estimated  costs);  and  indirect  costs  associated
with  patients  aged  65  years  and  over,  as  the  authors  took  the
conservative  option  of  considering  that  only  patients  under
65  are  productive.
However,  this  conservative  methodological  approach  not
only  shows  the  criteria  used  in  estimating  calculations  in  a
positive  light,  it  also  tells  us  how  much  HF  is  actually  cost-
ing  this  country.  Life  expectancy  at  birth  in  Portugal  rose  by
over  four  years  between  2000  and  2015,  to  81.3  years,  and
most  of  the  gains  in  life  expectancy  since  2000  have  been
after  the  age  of  65.20 Along  with  the  continuing  need  to  pre-
vent  HF  by  controlling  cardiovascular  risk  factors  throughout
life,  efforts  should  be  made  to  improve  early  diagnosis  of
HF  and  also  to  reduce  the  need  for  hospitalization,  which  is
largely  responsible  for  the  cost  of  the  condition.  Innovative
strategies  like  remote  invasive  monitoring  have  been  shown
to  reduce  the  risk  of  recurrent  HF  hospitalization21 and
have  a  favorable  cost-effectiveness  profile.22,23 Additionally,
the  TIM-HF  2  study  on  non-invasive  monitoring  suggested
that  a  structured  remote  patient  management  intervention,
when  used  in  a  well-defined  HF  population,  could  reduce
the  percentage  of  days  lost  due  to  unplanned  cardiovascu-
lar  hospital  admissions  and  all-cause  mortality.24 According
1
15
o  the  European  Society  of  Cardiology’s  2019  clinical  prac-
ice  update  on  heart  failure,  a  similar  approach  to  that  used
n  TIM-HF  2  may  be  considered  to  reduce  the  risk  of  recur-
ent  cardiovascular  and  HF  hospitalizations  and  the  risk  of
ardiovascular  death.25 These  and  other  strategies  may  be
ested,  but  their  cost/benefit  ratio  needs  to  be  appropri-
tely  assessed.
COI  studies  are  an  essential  tool  for  providing  health  pro-
essionals  and  health  policy  makers  with  information  on  cost
rivers,  facilitating  targeted  decision-making  regarding  allo-
ation  of  costs  and  resources.15 The  study  by  Gouveia  et  al.13
rovides  key  information  in  this  regard  and  can  be  used  as
he  basis  for  other  economic  assessments.
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